CDKN2A and non-small cell lung carcinoma: A study by Gutiontov et al. showed that NSCLC harboring a CDKN2A loss-of-function mutation had a twofold increase in immunotherapy resistance, irrespective of PD-L1 expression, and a poorer clinical outcome [23].